Therapeutics News and Research

RSS

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.

22 Sep 2011

Theraclone initiates TCN-032 Phase 1 trial in influenza A

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-032, a broadly protective, fully human monoclonal antibody for the treatment of influenza A virus.

22 Sep 2011

Digna Biotech receives FDA Orphan Drug status for cardiotrophin-1 to treat ALF

Digna Biotech, a Spanish biotechnological company, announces that the Food and Drug Administration (FDA) granted cardiotrophin-1 (CT-1) Orphan Drug status for use in the treatment of acute liver failure.

22 Sep 2011

NIH-funded project to develop new class of tissue regeneration therapeutics

The National Institutes of Health (NIH) has awarded nearly $2 million to researchers at the Georgia Institute of Technology and Emory University to develop a new class of therapeutics for treating traumatic injuries and degenerative diseases.

22 Sep 2011

Positive data from InVivo's biomaterial scaffold implant preclinical study on acute SCI

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that in a rodent contusion model of SCI the Company's proprietary biopolymer scaffold showed positive preliminary data that indicate a therapeutic effect.

21 Sep 2011

Clinical trial to evaluate TAU's stem cell technology for ALS

The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

21 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

Regulatory bias against taking oral anti-cancer medications with food places patients at risk of overdose

A regulatory bias against taking oral anti-cancer medications with food places many patients at increased risk for an overdose and forces them to "flush costly medicines down the toilet," argues Mark Ratain, MD, an authority on cancer-drug dosing.

20 Sep 2011

Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data from a preclinical study evaluating the efficacy its NDV-3 vaccine in a model of vulvovaginal candidiasis (VVC), which is primarily caused by Candida albicans.

20 Sep 2011

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive Phase 1 data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

19 Sep 2011

Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis

Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.

19 Sep 2011

Aestus to develop ATx09-002 for treatment of neuropathic pain

Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357.

19 Sep 2011

Techulon signs distribution agreement with BioConcept for Glycofect

Techulon Inc., the leader in low-toxicity gene delivery has signed a distribution agreement with BioConcept of Allschwil, Switzerland.

19 Sep 2011

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced that data about hypoparathyroidism will be presented at the 2011 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in San Diego, CA, September 16-20, 2011.

19 Sep 2011

Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis

Tarsa Therapeutics today presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA-, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.

19 Sep 2011

MDC Partners acquires majority stake in Concentric Pharma Advertising

MDC Partners announced today that they have acquired a majority stake in leading healthcare and pharma advertising and marketing agency, Concentric Pharma Advertising.

17 Sep 2011

HHS' BARDA contract advances development of novel anthrax vaccine, antitoxin

The advanced development of a novel next-generation anthrax vaccine and a new type of anthrax antitoxin have received support through new contracts funded the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

16 Sep 2011

Teva to invest in CDI for development of novel antiviral drugs

Teva Pharmaceutical Industries Ltd. announced today that it has signed a collaboration option to license and share purchase agreements to invest in Cocrystal Discovery Inc. (CDI), a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases.

16 Sep 2011

TCT to showcase major scientific research breakthroughs in cardiovascular medicine

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world's leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

16 Sep 2011

Potential new treatment for fragile X syndrome

Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.

16 Sep 2011

Therapeutics News and Research

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

Theraclone initiates TCN-032 Phase 1 trial in influenza A

Digna Biotech receives FDA Orphan Drug status for cardiotrophin-1 to treat ALF

NIH-funded project to develop new class of tissue regeneration therapeutics

Positive data from InVivo's biomaterial scaffold implant preclinical study on acute SCI

Clinical trial to evaluate TAU's stem cell technology for ALS

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Regulatory bias against taking oral anti-cancer medications with food places patients at risk of overdose

Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

Tarsa reports positive data from OSTORA Phase III ORACAL trial for postmenopausal osteoporosis

Aestus to develop ATx09-002 for treatment of neuropathic pain

Techulon signs distribution agreement with BioConcept for Glycofect

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

Positive data from Tarsa's OSTORA Phase III trial on postmenopausal osteoporosis

MDC Partners acquires majority stake in Concentric Pharma Advertising

HHS' BARDA contract advances development of novel anthrax vaccine, antitoxin

Teva to invest in CDI for development of novel antiviral drugs

TCT to showcase major scientific research breakthroughs in cardiovascular medicine

Potential new treatment for fragile X syndrome

Next-generation therapeutics eBook eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News